Based in Nottingham, UK, the company is a spin-out from the University of Nottingham, based on the research of Professor Kevin Shakesheff - a world-leading key opinion leader in regenerative medicine.
Based in Nottingham, UK, the company is a spin-out from the University of Nottingham, based on the research of Professor Kevin Shakesheff – a world-leading key opinion leader in regenerative medicine. The business initially conducted contract research work for several prestigious healthcare companies, which led to the signing of a development agreement with Heraeus Medical, for the development of an antibiotic releasing bone graft.
The company received its first seed funding from Mercia Asset Management in 2018. This has allowed the acceleration of its research into LB001, and the continued discovery in multiple new orthobiologic areas.
We are currently pursuing multiple high value orthobiologic opportunities in spinal indications.
Our vision is to become internationally recognised as a company that helps people with debilitating spinal conditions regain control of their lives. We do this by being curious about what is possible but grounding our work in robust science. We challenge ourselves to bring disruptive products to clinical areas where patients will benefit the most.